China Pharma Holdings (CPHI) FCF Margin (2010 - 2026)
China Pharma Holdings' (CPHI) quarterly FCF Margin came in at 3.46% in Q2 2026, down 3021.0% on a YoY basis from 0.12% in Q2 2025, and up 38.42% quarter-over-quarter from 5.62% in Q1 2026.
Powered by 
Analysis
China Pharma Holdings (CPHI) FCF Margin (2010 - 2026) Analysis & Trends
China Pharma Holdings (CPHI) has reported FCF Margin for 17 consecutive years, with 3.46% the latest figure, recorded in Q2 2026.
- For the quarter ending Q2 2026, FCF Margin fell 3021.0% year-over-year to 3.46%; the trailing twelve-month figure through Jun 2026 stood at 3.62% (down 1235.0% YoY), and the FY2025 full-year result was 2.15%, up 1196.0% from the prior year.
- FCF Margin climbed to 3.46% in Q2 2026 per CPHI's latest filing, from 5.62% in the prior quarter.
- Across five years, FCF Margin topped out at 52.11% in Q3 2023 and bottomed at 72.04% in Q1 2023.
- Historically, FCF Margin has averaged 8.1% across 5 years, with a median of 4.54% in 2026.
- The sharpest annual moves came in 2022 and 2023: FCF Margin sank 5955 bps in 2022, then jumped 5381 bps in 2023.
- Over 5 years, FCF Margin stood at 20.95% in 2022, then plunged by 106 bps to 1.25% in 2023, then soared by 2071 bps to 24.62% in 2024, then sank by 50 bps to 12.36% in 2025, then tumbled by 128 bps to 3.46% in 2026.
- According to Business Quant data, FCF Margin over the past three periods registered 3.46%, 5.62%, and 12.36% for Q2 2026, Q1 2026, and Q4 2025 respectively.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 643.26 Bn | 622.50 Bn | 17.26 Bn | 28.82% |
| 2 | AbbVie | 443.31 Bn | 436.74 Bn | 12.70 Bn | 18.33% |
| 3 | Merck | 364.74 Bn | 357.60 Bn | 12.21 Bn | 26.96% |
| 4 | Novartis Ag | 266.46 Bn | 258.77 Bn | 11.24 Bn | 43.05% |
| 5 | Pfizer | 158.57 Bn | 146.88 Bn | 10.94 Bn | 2.01% |
| 6 | Sanofi | 52.33 Bn | 44.95 Bn | 10.79 Bn | 25.52% |
| 7 | Revolution Medicines | 43.79 Bn | 43.79 Bn | - | - |
| 8 | Incyte | 25.23 Bn | 20.69 Bn | 1.57 Bn | 29.58% |
| 9 | United Therapeutics | 21.67 Bn | 19.01 Bn | 683.80 Mn | 26.25% |
| 10 | China Pharma Holdings | 31.39 Mn | 31.08 Mn | 83,566.00 | -3.46% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | -3.46% |
| Mar 31, 2026 | -5.62% |
| Dec 31, 2025 | 12.36% |
| Sep 30, 2025 | -27.10% |
| Jun 30, 2025 | 26.75% |
| Mar 31, 2025 | -11.62% |
| Dec 31, 2024 | 24.62% |
| Sep 30, 2024 | -3.43% |
| Jun 30, 2024 | -7.86% |
| Mar 31, 2024 | -42.72% |
| Dec 31, 2023 | -1.25% |
| Sep 30, 2023 | 52.11% |
| Jun 30, 2023 | -19.30% |
| Mar 31, 2023 | -72.04% |
| Dec 31, 2022 | 20.95% |
| Sep 30, 2022 | -1.70% |
| Jun 30, 2022 | -31.56% |
| Mar 31, 2022 | -54.91% |
| Dec 31, 2021 | -7.10% |
| Sep 30, 2021 | -43.81% |